Next Article in Journal
Functionalization of 3D-Printed Titanium Scaffolds with Elastin-like Recombinamers to Improve Cell Colonization and Osteoinduction
Previous Article in Journal
The In Vitro, Ex Vivo, and In Vivo Effect of Edible Oils: A Review on Cell Interactions
Previous Article in Special Issue
Ultrasound-Assisted Extraction of Cannabinoids from Cannabis Sativa for Medicinal Purpose
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 15
Issue 3
10.3390/pharmaceutics15030870
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Digital Technologies Applied to Control the One-Step Process of Cannabis Olive Oil Preparations

by
Paolo Bongiorno
1,†,
Antonio Lopalco
2,†,
Antonella Casiraghi
3,
Antonio Spennacchio
2,
Alessandro Pitruzzella
4,
Angela Assunta Lopedota
2,
Paola Minghetti
3 and
Nunzio Denora
2,*
1
Farmacia Dott. Paolo Bongiorno, Via Vittorio Veneto 17/19, 92026 Favara, AG, Italy
2
Department of Pharmacy—Pharmaceutical Sciences, The University of Bari Aldo Moro, Via Orabona 4, 7012 Bari, BA, Italy
3
Department of Pharmaceutical Sciences, The University of Milan Via G. Colombo 71, 20133 Milan, MI, Italy
4
Biomedicine, Neuroscience and Advanced Diagnostics, (BIND) University of Palermo, Piazza Marina, 61, 90133 Palermo, PA, Italy
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to the work.
Pharmaceutics 2023, 15(3), 870; https://doi.org/10.3390/pharmaceutics15030870
Submission received: 15 January 2023 / Revised: 16 February 2023 / Accepted: 6 March 2023 / Published: 8 March 2023
(This article belongs to the Special Issue New Perspectives for the Administration of Cannabis for Medical Use: From Traditional to Advanced Formulations. What Next?)
Browse Figures
Versions Notes

Abstract

:
The reproducibility of an extemporaneous preparation is an essential condition for guaranteeing the quality, efficacy, and safety of the medicinal product. This study aimed to develop a controlled one-step process for cannabis olive oil preparations by applying digital technologies. For this purpose, the chemical profile of cannabinoid contents in oil extracts of Bedrocan, FM2, and Pedanios varieties obtained with the already in use method, proposed by the Italian Society of Compounding Pharmacists (SIFAP), was compared with two new methods, specifically the Tolotto Gear® extraction method (TGE) and the Tolotto Gear® extraction method preceded by a pre-extraction procedure (TGE-PE). HPLC analyses showed that the concentration of THC using cannabis flos with a high THC content (over 20% w/w) was always higher than 21 mg/mL for the Bedrocan variety and close to 20 mg/mL for the Pedanios variety when applying TGE, while with TGE-PE, the THC concentration was higher than 23 mg/mL for the Bedrocan variety. For the FM2 variety, the amounts of THC and CBD in the oil formulations obtained using TGE were higher than 7 mg/mL and 10 mg/mL, respectively, and for TGE-PE, the concentrations of THC and CBD were higher than 7 mg/mL and 12 mg/mL, respectively. GC-MS analyses were performed to define the terpene contents in the oil extracts. The samples of Bedrocan flos extracted with TGE-PE displayed a distinctive profile, highly rich in terpenes and devoid of oxidized volatile products. Thus, TGE and TGE-PE allowed performing a quantitative extraction of cannabinoids and increasing the total mono-di-tri terpenes and sesquiterpene concentrations. The methods were repeatable and applicable to any quantity of raw material, preserving the phytocomplex of the plant.

1. Introduction

Cannabis sativa L. is an annual cycle herbaceous flowering plant belonging to the Cannabinaceae family [1,2]. The plant is known to contain more than eight hundred compounds, among which the most important classes of active constituents are cannabinoids, terpenes, and flavonoids. Cannabinoids, a class of terpenophenolics [3], are abundantly produced in the glandular trichomes on female flowers [4]. Among them, the two most representative compounds are Δ9-tetrahydrocannabinolic acid (THCA) and cannabidiolic acid (CBDA) (Figure 1). These two acidic cannabinoids undergo a spontaneous decarboxylation under the action of light and heat, leading to formation of Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) (Figure 1) [5].
THC, the main psychoactive constituent, is the most important active compound present in cannabis varieties used for either medical or recreational purposes [6]. CBD, present in fiber-type and medicinal Cannabis sativa varieties [6,7,8], also displays various pharmacological activities, such as antioxidant, anti-inflammatory, anti-microbial [9,10,11], and neuroprotective activity [12], related to the acting on several targets [9].
Terpenes are an additional well-represented class of active compounds produced in cannabis inflorescences [7,10]. Among terpenes, myrcene (Figure 1), limonene, trans-ocimene, and terpinolene are the most represented monoterpenes in the plant, while caryophyllene (Figure 1) and humulene are the most abundant sesquiterpenes [7,10]. Cannabis-based treatments represent a promising opportunity, as indications suggest a synergistic effect between cannabinoids and terpenes that is superior to synthetic drugs, known as the “entourage effect” [13,14,15,16,17].
Dried female flower tops of the plant are available as standardized medicinal grade material. The most common medical indications of cannabis include neuropathic pain [13]; chronic pain resistant to non-steroidal anti-inflammatory drugs, corticosteroids, or opioids; glaucoma resistant to conventional therapies [18]; undernutrition; chemotherapy-induced nausea and vomiting [19,20]; spasticity; and seizure in multiple sclerosis [20,21,22]. It is also a helpful therapeutic agent against cachexia and anorexia in patients with cancer or autoimmune disease syndrome and also in the reduction of body movements in Gilles de la Tourette syndrome [23].
Medical cannabis in Italy, as in the rest of the European Union, represents an irregular situation [15,24,25]. Dutch Bedrocan® varieties (such as Bedrocan®, Bediol®, Bedica®, and Bedrolite®), and the two strains FM1 and FM2 produced by the Military Pharmaceutical Chemical Institute of Florence, Italy, can be prescribed together with other imported brands regulated by tenders of the Italian Ministry of Health [26]. Medical cannabis-based prescriptions are increasing in several countries, where therapeutic use is authorized; this is due to the positive role of cannabis in treating several pathological conditions, with few side effects [27,28]. Therefore, in many countries, pharmacists are legally allowed to formulate cannabis inflorescence doses for infusions, micronized capsules, vaping, and macerated oils [22,28,29,30].
In the case of pharmacy compounding, it is important to find extraction methods that allow the preservation of the complex cannabinoids/terpenes in products used for therapeutic purposes. Medical cannabis preparations can be used either orally or via inhalation [31]. As regards medical cannabis oils for oral therapeutic use, several extraction methods have been described in the literature [2,15,30,31,32,33,34]. Among them, in 2016 the Italian Society of Compounding Pharmacists (SIFAP) developed and proposed a method for preparing cannabis oil galenic extracts characterized by high yields [15]. The SIFAP method is a two-step procedure described for the preparation of a small oily extract batch, specifically 5 g of inflorescences extracted in 50 mL of pharmacopeia-grade olive oil, which does not allow controlling the entire decarboxylation process of cannabinoids.
In relation to the formulation of medical cannabis oils, no attention is generally paid to the terpene components of the plant. Indeed, the decarboxylation process, which is usually applied to the plant material to convert cannabinoids from the acidic into the neutral forms (Figure 1), can cause a complete loss of these volatile components. Since the method and conditions of cannabis oil preparation can have an impact on the composition of the formulation, the development and optimization of an efficient one-step procedure to be followed by pharmacists is important, to obtain a final formulation of high quality and to assure the reproducibility of its therapeutic outcomes. To our knowledge, none of the described procedures for cannabis oil preparation guarantee standardized oily extracts, in particular if applied to larger quantities of cannabis inflorescences, producing oleolites with a different content of active molecules. This limit is reflected by the difficulty in comparing clinical trials, in which extracts with different characteristics are often used.
In the light of all the above, in this study, with the aim of obtaining cannabis oily extracts rich in cannabinoids and terpenes, two extraction methods were evaluated. The extraction process was performed using an innovative technology, named Pharmagear®. This instrumentation integrated an automated process control system, able to control the temperature and the magnetic stirring during the extraction process, and a reactor (Tolotto) in which extraction and decarboxylation of the phytocomplexes occurred in a single-step.

2. Materials and Methods

2.1. Chemical and Solvent

In this study, several batches of Cannabis sativa L. varieties were used and purchased from different providers. Bedrocan (THC = 19–22%; CBD <1%) was purchased from the providers Farmalabor srl (Canosa di Puglia, BT, Italy), Fagron Italia srl (Quarto Inferiore, BO, Italy) and Galeno srl (Carmignano, PO, Italy). Cannabis Aurora Pedanios (THC 17–26%; CBD <1%) and FM2 (THC 5–8%; CBD 7.5–12%) were purchased from the Military Pharmaceutical Chemical Institute—Agenzia Industrie Difesa (Florence, FI, Italy). Caelo extra virgin olive oil (European Pharmacopoeia 9.3 (Eur. Ph. 9.3)) was purchased from Comifar Distribuzione SPA (Novate Milanese, MI, Italy). Cannabinoid standards (T-093-1 mL Δ9-Tetrahydrocannabinolic Acid; T-108-0.5 mL THC Cannabinoids Mixture-3; C-144-1 mL Cannabidiolic Acid (CBDA) used for chromatography were of analytical quality and were purchased from Merck (Milan, MI, Italy). Alpha-tocopherol (Eur. Ph.) was also purchased from Merck (Milan, MI, Italy).

2.2. Pharmagear® Apparatus and Instruments

For the preparation of cannabis oils, an innovative technology named Pharmagear® (Energicamente srl, Favara, AG, Italy; Nebiolo Ht, Assoro, EN, Italy) was used (Figure 2). This instrument brings together a reduced pressure evaporator, an essential oil extractor constituted of a macerator coupled with an intelligent magnetic stirrer, and a reactor (Figure 2a–c). The extraction and decarboxylation processes are controlled by an automated electronic control system that sends in real time all the acquired data to software PharmaGear 1.0 (Energeticamente srl, Favara, AG, Italy) on a PC. This allows monitoring and controlling the entire decarboxylation process and measuring the CO2 produced during the heating phase with a specific CO2 probe (Figure 2d).
Times and temperatures are programmed using a software program before preparation. The system adapts its behavior according to pre-established temperatures, the preparation time, the phases of extraction and decarboxylation, the quantity of raw material to be heated, and environmental variables. The following equipment was also necessary for the preparation of the cannabis oils: Baoshishan FS-600 N Sonicator Ultrasonic Homogenizer 600 W Lab Sonicator Processor (Toption Instrument Co., Ltd., Xi’an, China); Turbo emulsifier Miccra Homogenizer (Riman SRL, Palermo, PA, Italy); vacuum pump filter system connected to the reactor.

2.3. Preparation of the Cannabis Extracts in Olive Oil

Regardless of the quantities of cannabis to be extracted, for a minimum batch, 5 g of Cannabis flos were weighed and 50 mL of Ph. Eur. Olive Oil, previously cooled to a temperature between 2 and 8 °C, were measured. The reactor was wrapped with ice gel. A 10 mL aliquot of the oil was stored and added at the end of the entire process, for washing the reactor. The remaining 40 mL of Ph. Eur. Olive Oil was introduced to the reaction dish, together with the inflorescences, previously micronized, and dispersed in oil using a homogenizer. Any remaining cannabis inflorescences stuck in the rotor/stator head of the homogenizer were moved using a spatula and a second mixing cycle was performed for several minutes. Then, the mixture in the ice-gel-wrapped reactor was sonicated with a probe (Baoshishan FS-600 N Sonicator Ultrasonic Homogenizer 600 W Lab Sonicator Processor) at a delivered power of approximately 200 W for 5 min and frequency of 20 kHz. A magnetic anchor was inserted into the reaction dish, which in turn was closed with an airtight lid. The vacuum pump was connected to the reactor head and the oxygen was eliminated to reduce the oxidative stress of the oil during the subsequent heating phases. The reactor was assembled with a control system (Figure 2c) and using the Tolotto Gear® extraction (TGE) method; two modes can be used: TGE alone or preceded by a pre-extraction procedure (TGE-PE). In particular, TGE consists in an extraction phase conducted at 110 °C for 120 min and a decarboxylation phase at 146 °C for 80 min, while TGE-PE requires a pre-extraction phase at room temperature (25–30 °C) for 12 h before starting the hot extraction process and subsequent decarboxylation, as described above for TGE (Figure 3). At the end of the process, the reactor was removed from the instrument and its temperature reduced to 40 °C with an ice gel wrap. The extracted cannabis oil was filtered using a food-grade nylon membrane filter system (pore size 37 μm) connected to a vacuum pump (VidaXL50 L/minpower 120 W, vacuum degree 50 Pa) (Figure 2f). The reactor and magnetic anchor were washed with the preserved oil fraction, which was added to the remaining oily preparation. The obtained cannabis oil was stored in an amber glass bottle, and alpha-tocopherol at 0.05% v/v was added to prevent oxidation. For batches with 10 and 15 g of plant material a 90- and 140-mL solvent volume of olive oil was used for the extraction process in the reactor, respectively. A 10 mL aliquot of oil was added at the end of the entire process to wash the reactor. In all the experiments, the drug:solvent volume ratio after dilution with 10 mL of washing solvent fraction was always maintained equal to 1:10.

2.4. Cannabis Extract in Olive Oil with the SIFAP Procedure (Maceration Process)

According to a method previously reported in literature [15], 5 g samples of Cannabis sativa L. were decarboxylated in an oven at 115 °C for 40 min. The plant material was then added to 50 mL of olive oil and further crumbled using a mixer. The extraction was performed at 100 °C over a period of 40 min, keeping an open beaker in a pre-heated and stirred silicone-oil bath. Then the mixture was immediately filtered, to obtain the final oil (Figure 3).

2.5. HPLC Instrument and Method

The HPLC instrument was an Agilent 1220 Infinity II LC gradient system VL equipped with a variable wavelength UV detector and openLab DCS software (Agilent Technologies, Waldbronn, Germany). An Agilent InfinityLab Poroshell 120 EC-C18 3.0 × 50 mm, 2.7 µm column thermostated at 50 °C was used. Linear gradient elution (Table 1) with a flow rate of 1.0 mL min−1 was used. UV detection was carried out at 230 nm. An injection volume of 5 μL was used in all experiments. The analysis time was 11 min (with 1.5 min for re-equilibration).

Calibration Curve

Standard calibrators were produced from CBD, CBDA, THC, THCA, and cannabinol (CBN) certified reference standards, each at a concentration of 1.0 mg/mL in organic solvent. Equivalent volumes of each standard were mixed and diluted with methanol to a concentration of 250 µg/mL. Four dilutions were made, to generate a calibration curve at concentrations of 250, 100, 50, 10, and 1.0 µg/mL. Calibration curves were created as a response to the concentration and used for accuracy, precision, and linearity determinations, as described by Storm and colleagues. The analytical method used was that described in Agilent’s “dedicated cannabinoid potency test in cannabis or hemp” [35]. LOD (0.15 μg/mL) and LOQ (0.50 μg/mL) were determined using the signal-to-noise ratio (S/N) (Instrumental LOD: S/N = 3 and LOQ: S/N = 10). The standard solutions were stored away from light at a temperature of −20 °C until use.

2.6. Sample Preparation and Analysis of Cannabinoids and Terpenes

Qualitative and quantitative analysis of the profile of cannabinoids in the cannabis oil formulations was carried out using the HPLC method described in Section 2.5. HPLC instrument and method. First, 50 µL or 500 µL aliquots of each homogenized concentrated cannabis oil were pipetted into a calibrated volumetric flask and diluted to a final volume of 5 mL with high purity HPLC grade ethanol. Then, 2 mL of each solution was filtered using a glass syringe fitted with a 0.45 μm regenerated cellulose syringe filter. An additional 10-fold dilution of the filtered solution was performed by transferring a 100 µL aliquot into an amber glass 2 mL auto-sampler vial and adding 900 µL high purity HPLC grade methanol. Then, the prepared samples were analyzed by HPLC.
The determination of terpene profile was carried out according to the method developed by Aiello and coworkers for the evaluation of volatile organic compounds [36].

2.7. Statistical Analysis

Concentrations of cannabinoids and terpenes in the analyzed samples were expressed both as mean values and related standard deviation (S.D.). Statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software, Inc., La Jolla, CA, USA). In order to reveal potential discriminating features between the groups, a one-way analysis of variance (ANOVA) test was performed. Bonferroni’s multiple comparison test (MCT) was applied as a post hoc test. The groups were designed considering the cannabis varieties (Bedrocan, Pedanios, and FM2) and extraction protocol (TGE, TGE-PE, and SIFAP). Significant variables were expressed by a p-value with a threshold < 0.05.

3. Results and Discussions

The preparation of pharmaceutical grade olive oil formulations of Cannabis sativa L. for medical use usually requires a decarboxylation step followed by an extraction procedure. The latter, called the SIFAP method, is one of the most widely used. In this study, the application of a new one-step technology aimed at protecting the phytocomplex from degradation during the extraction procedure was studied. By means of a new technological platform, named Pharmagear®, two methods, named TGE and TGE-PE, for the preparation of pharmaceutical grade olive oil formulations were compared, in terms of yields of extracted cannabinoids and terpenes.
Cannabinoid quantification was obtained using HPLC, and a representative chromatogram is reported in Figure 4.
Table 2 shows the amounts of THC, THCA, CBN, CBD, and CBDA obtained using the TGE and TGE-PE methods. At the beginning of 2022, the Pedanios variety was not supplied by any provider to complete the study using TGE-PE; therefore, it was only possible to carry out experiments using TGE. The concentrations (mg/mL) of the active ingredients are expressed as mean values with their standard deviation (S.D.). Cannabinoid concentrations were found to be in line with data available in the literature for each vegetal material preparation [2,28,31].
Since the extractive yield and decarboxylated products was always close to 100% of the achievable result (considering that Bedrocan and Pedanios have a declared THC content in the plant (sum of THC and THCA) close to or higher than 20% w/w and FM2 has a declared content of THC in the plant in a range of 5–8% w/w and of CBD 7.5–12% w/w), overall the TGE and TGE-PE methods appeared almost equivalent in terms of the cannabinoids extracted (Table 2). These results were compared to those obtained using the SIFAP method, one of the most widespread high-capacity extraction methods. The comparison was performed on the basis of data reported in the literature and a new experimental dataset.
Over the period from 2017 to 2019, hundreds of samples were prepared by pharmacists and analyzed by the University of Milan [34]. Despite a THC content close to or greater than 20% w/w, an average extraction of 12.236 ± 3.31 mg/mL was obtained using the Cannabis flos varieties Bedrocan and Pedanios (n = 800), while residual THCA was less than 1.8 mg/mL. In the case of FM2 (n = 350), the THC mean value was 5.06 ± 1.01 mg/mL and CBD was 7.268 ± 1.84 mg/mL (Table 3).
The extraction capacities of the two proposed methods (Table 2) using the innovative platform were almost doubled compared to those described in the literature [34]. The concentration of THC using cannabis flos with high THC content (over 20% w/w) was always higher than 21 mg/mL for the Bedrocan variety and close to 20 mg/mL for the Pedanios variety when applying the TGE method, while for with TGE-PE method used with the Bedrocan variety, the THC concentration was higher than 23 mg/mL. A significant difference (p value < 0.01) was found between the THC quantities in oil formulations from the Bedrocan variety obtained when applying the TGE and TGE-PE methods. Moreover, for FM2, the amounts of THC and CBD in the oil formulations obtained using the TGE method were higher than 7 mg/mL and 8 mg/mL, respectively (Table 2), and for the TGE-PE method, the concentrations of THC and CBD were higher than 7 mg/mL and 12 mg/mL, respectively (Table 2). The THC quantities extracted from the FM2 variety with both TGE and TGE-PE methods were higher and statistically significant (p values < 0.01) than the mean values reported in literature [34] (Table 3), while the CBD quantities extracted from the FM2 variety with only TGE-PE method were statistically significant (p values < 0.01) compared to the SIFAP results. No significant differences between the THC contents in oil formulations produced using different amounts of cannabis flos and olive oil (5:50, 10:100 and 15:150, Table 2) were observed. The results of the tests carried out with three different quantities of plant material support that the methods are also suitable for multiple batches. Some differences in terms of the amounts of THCA and CBDA determined in the HPLC analysis using different amounts of cannabis flos and oil could be attributed to the residual contents of these cannabinoids in the various batches of plant materials purchased from different suppliers.
To confirm the advantages offered by the new platform Pharmagear®, the TGE method was compared with new experimental SIFAP results (maceration process). Table 4 shows the content in mg/mL of cannabinoids in the oil formulations after extraction of 5 g of the cannabis flos variety Bedrocan.
As one can see from Table 4, the obtained experimental results were in agreement with the data reported in the literature [34]. The THC content in the oil formulation produced using the TGE method was significantly different (p < 0.01) from the content in the formulation obtained using the maceration process.
The characteristic scent of cannabis is the result of the presence of about 140 different terpenes and terpenoids. Terpenes are a mixture of different compounds consisting of multiples of the isoprene unit (C5H8). β-myrcene, limonene, trans-ocimene, and α-terpinolene are the most abundant monoterpenes in cannabis inflorescences, while β-caryophyllene and α-humulene are the most represented sesquiterpenes. These compounds have antioxidant, anti-inflammatory, anxiolytic, and anti-bacterial properties. During the preparation process of most oleolites produced with various methods, the heating that is applied to the plant material to convert the acidic cannabinoids into neutral compounds greatly reduces the lighter terpene percentage (monoterpenes). The use of high temperatures increases the concentration of sesquiterpenes, to the detriment of monoterpenes. To overcome this problem, the TGE method was designed to perform an extraction in a hermetic environment, so as to allow the condensation of the terpenes after cooling and under vacuum, in order to eliminate the oxidative stress of the oil during heating. In this study, a preliminary investigation into the ability of the TGE and TGE-PE methods to extract and preserve terpenes using the innovative technology Pharmagear® was conducted. TGE-PE differs from the former because it uses a pre-extraction of 12 h at a temperature of 30 °C.
The concentrations in mg/Kg of the terpenes extracted from Bedrocan flos are presented in Table 5. The concentrations of terpenes were found to be in line with the data available in the literature for oil preparations [25,31]. The quantity of preserved terpenes can be used as an indication of preservation of the phytocomplexes.
Mono-di-tri terpenes were highly represented in the analyzed sample (Table 5). Overall, the two methods showed a different performance, in terms of the final quantitative yield of the extracted terpenes. On the other hand, the sample of Bedrocan flos extracted with the TGE-PE method displayed a distinctive profile, highly rich in terpenes and devoid of oxidized volatile products. The quantified molecules belonging to this chemical class were α-pinene, limonene, and β-caryophyllene, showing a significant increasing trend when performing pre-extraction procedures compared to the TGE method. TGE-PE showed a greater extraction capacity in terms of the terpenes obtained. About 6% more active ingredients were extracted than the amount extracted using the TGE method (Table 5), even if for the less representative terpenes, in terms of concentration, this difference was amplified. Moreover, some terpenes could only be extracted using the TGE-PE method (Table 5). Cis-p-menth-2,8-dienol, α-limonene diepoxide, α-guaiene, and 5-caranol (Table 5) were only present in the oil formulation obtained using the TGE-PE method and absent in the extraction with the TGE method.
Using the new platform, the two proposed methods allow preserving the terpene fractions, with no increase in sesquiterpenes to the detriment of monoterpenes.
During the decarboxylation process, it was possible to observe an increase in the internal pressure of the bath, with consequent compensation for the negative pressure, due to the formation of CO2. This phenomenon is an indication of decarboxylation. The total cooling of the Tolotto before its opening is decisive and is optimized to allow the condensation and recovery of the terpenes, which otherwise would be lost. Moreover, the very low concentration of CBN indicated a low degradation of THC, and together with the high THC values, this confirmed the validity of the methods. The cooling of the Tolotto allowed the condensation of the terpenes and its tightness determined the redissolution of the vapor phase in the solvent according to Henry’s law (a gas that exerts pressure on the surface of a liquid enters the solution until it has reached the same pressure it exerts on it). By increasing the pressure above the liquid proportionally, this increased the quantity of gas that passed into solution. The division of the methods into two parts, extraction and decarboxylation in the Tolotto, is purely ideal, in the sense that part of the decarboxylation occurred during extraction and vice versa.
The new technology described in this study and the two extraction methods used are very promising for both procedures for preparation of an extemporaneous oil formulation from Cannabis sativa L. for medical use and the standardization of the chemical composition of the bioactive molecules in extracts, and especially for the presence of terpenes (as one can see from the preliminary results in Table 5). Among these, limonene, pinene, myrcene, and β-caryophyllene, compounds known to be individually responsible for the anti-inflammatory, analgesic, antinociceptive, anxiolytic, and synergistic effects with phytocannabinoids [17,37,38], were present in a high concentrations in the oleolites produced using the TGE and TGE-PE methods.
In this context, a differential cannabinoid receptor activity and the inhibition of glycoprotein-P [39,40] by terpenes have been studied and established. Moreover, many studies have demonstrated terpene enhancement of the absorption of several active pharmaceutical ingredients, such as analgesics and anti-inflammatories [41,42,43,44,45,46]. In addition, a cannabis formulation containing essential terpenes had a multi-target synergy [47]. In fact, each component of the phytocomplex could exert low therapeutic potency, but their concurrent pharmacological action was shown to be highly effective and characterized by a low toxicity [48]. Thus, it is important to formulate cannabis oil preparations characterized by a high cannabinoid and terpene content.

4. Conclusions

To standardize the extraction conditions for medical cannabis oily preparations, SIFAP offers a suitable procedure to pharmacists. Several methods have also been proposed and adopted, but all of them are based on two separate steps: extraction and decarboxylation processes. The TGE and TGE-PE methods, based on an innovative automatic platform, allowed the extraction of the phytocomplex in a single step, controlling the entire decarboxylation process of cannabinoids. HPLC analyses performed on the oil formulations showed that the extraction capacities of the two proposed methods using the innovative platform were almost double compared to those obtained using the SIFAP procedure. The content of THC in the oil formulations was higher than 21 mg/mL for the Bedrocan variety and close to 20 mg/mL for the Pedanios variety when applying TGE, while with TGE-PE, the THC concentration was higher than 23 mg/mL for the Bedrocan variety. For the FM2 variety, the amounts of THC in the oil formulations obtained using TGE and TGE-PE were higher than 7 mg/mL. GC-MS analyses of the oil formulations obtained from Bedrocan flos extracted with TGE-PE displayed a distinctive profile highly rich in terpenes and devoid of oxidized volatile products. Thus, the application of TGE and TGE-PE extraction methods permitted producing standardized oily formulations with an increased composition of cannabinoids and total mono-di-tri terpenes and sesquiterpene concentrations.
The results obtained are relevant and allow exploring a new way of thinking about preparations in the galenic laboratory. Modern and accurate preparation process control systems establish the entrance of the Technology of Industry 4.0 or “Smart Factory” into the galenic laboratory and lend themselves to further application developments. The automation and accuracy of the system does not require the continuous control of an operator during the preparation phases and allow for accuracy, repeatability, and the avoidance of human error. The developed equipment proved useful, not only for the preparation of oil, but also for decarboxylated capsules based on medical cannabis. Based on the initial evaluation of the results obtained through this new technology, further studies will be conducted, in consideration of the fact that the literature on the terpene profile present in extracts of oily medical cannabis is very scarce.

5. Patent

An Italian patent was granted by the Italian Office for Patent and Brands for the procedure for Cannabis oil production (patent number 102019000014901, 3 August 2021).

Author Contributions

Conceptualization, P.B., N.D. and A.L.; methodology, P.B.; validation, P.B., P.M. and N.D.; formal analysis, P.B., A.C, A.S. and A.A.L.; investigation P.B., A.C., A.S., and A.A.L.; resources, P.B.; data curation, P.B., A.S., A.A.L. and A.L.; writing—original draft preparation, A.L., N.D. and P.B.; writing—review and editing, A.L., A.A.L., N.D., P.B. and A.P.; visualization, A.A.L. and N.D.; supervision, P.B., A.L., P.M. and N.D.; project administration, A.L. and P.B.; funding acquisition, P.B. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding from agencies in the public, commercial, or not-for-profit sectors.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

The authors would like to thank Pasquale Alba, Alfredo Silvano, and Diego Zagarella from Energicamente s.r.l., Favara (AG), Italy for their technical assistance. The authors are also grateful to the University of Bari Aldo Moro and to the University of Milano.

Conflicts of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. Hartsel, J.A.; Eades, J.; Hickory, B.; Makriyannis, A. Cannabis Sativa and Hemp, Cannabis Sativa and Hemp; Gupta, R.C., Ed.; Nutraceuticals: Efficacy, Safety and Toxicity; Elsevier Inc.: London, UK, 2016; pp. 735–754. [Google Scholar]
  2. Ternelli, M.; Brighenti, V.; Anceschi, L.; Poto, M.; Bertelli, D.; Licata, M.; Pellati, F. Innovative methods for the preparation of medical Cannabis oils with a high content of both cannabinoids and terpenes. J. Pharm. Biomed. Anal. 2020, 186, 113296. [Google Scholar] [CrossRef]
  3. Andre, C.M.; Hausman, J.F.; Guerriero, G. Cannabis sativa: The plant of the thousand and one molecule. Front. Plant Sci. 2016, 7, 1–17. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Appendino, G.; Chianese, G.; Taglialatela-Scafati, O. Cannabinoids: Occurence and medicinal chemistry. Curr. Med. Chem. 2011, 18, 1085–1099. [Google Scholar] [CrossRef] [PubMed]
  5. Thomas, B.F.; ElSohly, M.A. The Analytical Chemistry of Cannabis: Quality Assessment, Assurance and Regulation of Medicinal Marijuana and Cannabinoid Preparations, 1st ed.; Elsevier: Amsterdam, The Netherlands; Oxford, UK; Waltham, MA, USA, 2015. [Google Scholar]
  6. Protti, M.; Brighenti, V.; Battaglia, M.R.; Anceschi, L.; Pellati, F.; Mercolini, L. Cannabinoids from Cannabis sativa L.: A new tool based on HPLC-DAD-MS/MS for a rational use in medicinal chemistry. ACS Med. Chem. Lett. 2019, 10, 539–544. [Google Scholar] [CrossRef]
  7. Pellati, F.; Brighenti, V.; Sperlea, J.; Marchetti, L.; Bertelli, D.; Benvenuti, S. New methods for the comprehensive analysis of bioactive compounds in Cannabis sativa L. (hemp). Molecules 2018, 23, 2639. [Google Scholar] [CrossRef] [Green Version]
  8. Brighenti, V.; Pellati, F.; Steinbach, M.; Maran, D.; Benvenuti, S. Development of a new extraction technique and HPLC method for the analysis of non-psychoactive cannabinoids in fibre-type Cannabis sativa L. (hemp). J. Pharm. Biomed. Anal. 2017, 143, 228–236. [Google Scholar] [CrossRef] [PubMed]
  9. Pellati, F.; Borgonetti, V.; Brighenti, V.; Biagi, M.; Benvenuti, S.; Corsi, L. Cannabis sativa L. and non-psychoactive cannabinoids: Their chemistry and role against oxidative stress, inflammation, and cancer. Biomed. Res. Int. 2018, 2018, 1691428. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  10. Iseppi, r.; Brighenti, V.; Licata, M.; Lambertini, A.; Sabia, C.; Messi, P.; Pellati, F.; Benvenuti, S. Chemical characterization and evaluation of the antibacterial activity of essential oils from Fibre-type Cannabis sativa L. (Hemp). Molecules 2019, 24, 2302. [Google Scholar] [CrossRef] [Green Version]
  11. Mechoulam, R.; Hanuš, L.O.; Pertwee, R.; Howlett, A.C. Early phytocannabinoid chemistry to endo-cannabinoids and beyond. Nat. Rev. Neurosci. 2014, 15, 757–764. [Google Scholar] [CrossRef] [PubMed]
  12. Corsi, L.; Pellati, F.; Brighenti, V.; Plessi, N.; Benvenuti, S. Chemical composition and in vitro neuroprotective activity of fibre-type Cannabis sativa L. (hemp). Curr. Bioact. Compd. 2019, 15, 201–210. [Google Scholar] [CrossRef]
  13. Russo, E.; Guy, G.W. A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med. Hypotheses 2006, 66, 234–246. [Google Scholar] [CrossRef]
  14. FDA Approves Liquid Marijuana for AIDS and Cancer Patients. Available online: https://hightimes.com/news/fda-approves-liquid-marijuana-for-aids-and-cancer-patients/ (accessed on 28 July 2016).
  15. Casiraghi, A.; Roda, G.; Casagni, E.; Cristina, C.; Musazzi, U.M.; Franzè, S.; Rocco, P.; Giuliani, C.; Fico, G.; Minghetti, P.; et al. Extraction Method and Analysis of Cannabinoids in Cannabis Olive Oil Preparations. Planta Med. 2018, 84, 242–249. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Russo, E.B.; Marcu, J. Cannabis pharmacology: The usual suspects and a few promising leads. Adv. Pharmacol. 2017, 80, 67–134. [Google Scholar]
  17. Russo, E.B. Taming THC: Potential Cannabis Synergy and Phytocannabinoid-Terpenoid Entourage Effects. Br. J. Pharmacol. 2011, 163, 1344–1364. [Google Scholar] [CrossRef] [PubMed]
  18. Navari, R.M. Management of chemotherapy-induced nausea and vomiting: Focus on newer agents and new uses for older agents. Drugs 2013, 73, 249–262. [Google Scholar] [CrossRef] [PubMed]
  19. Finnerup, N.B.; Attal, N.; Haroutounian, S.; Mcnicol, E.; Baron, R.; Dworkin, R.H.; Gilron, L.; Haanpää, M.; Hansson, P.; Jensen, T.S.; et al. Pharmacotherapy for neuropathic pain in adults: A systematic review and meta-analysis. Lancet Neurol. 2015, 14, 162–173. [Google Scholar] [CrossRef] [Green Version]
  20. Leussink, V.I.; Husseini, L.; Warnke, C.; Broussalis, E.; Hartung, H.P.; Kieseier, B.C. Symptomatic therapy in multiple sclerosis: The role of cannabinoids in treating spasticity. Adv. Neurol. Disord. 2012, 5, 255–266. [Google Scholar] [CrossRef] [Green Version]
  21. Haney, M.; Gunderson, E.W.; Rabkin, J.; Hart, C.L.; Vosburg, S.K.; Comer, S.D.; Foltin, R.W. Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep. J. Acquir. Immune Defic. Syndr. 2007, 5, 545–554. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Ramella, A.; Roda, G.; Pavlovic, R.; Cas, M.D.; Casagni, E.; Mosconi, G.; Cecati, F.; Minghetti, P.; Grizzetti, C. Impact of Lipid Sources on Quality Traits of Medical Cannabis-Based Oil Preparations. Molecules 2020, 25, 2986. [Google Scholar] [CrossRef]
  23. Palmieri, B.; Laurino, C.; Vadalà, M. Spontaneous, anecdotal, retrospective, open-label study on the efficacy, safety and tolerability of Cannabis galenical preparations (Bedrocan). Int. J. Pharm. Pract. 2019, 27, 264–270. [Google Scholar] [CrossRef] [Green Version]
  24. Calvi, L.; Pavlovic, R.; Panseri, S.; Giupponi, L.; Leoni, V.; Giorgi, A. Quality Traits of Medical Cannabis sativa L. Inflorescences and Derived Products Based on Comprehensive Mass-Spectrometry Analytical Investigation. In Recent Advances in Cannabinoid Research; Costain, W., Laprairie, R., Eds.; IntechOpen: London, UK, 2018; Available online: https://www.intechopen.com/chapters/63068 (accessed on 5 November 2018).
  25. Pavlovic, R.; Nenna, G.; Calvi, L.; Panseri, S.; Borgonovo, G.; Giupponi, L.; Cannazza, G.; Giorgi, A. Quality traits of “cannabidiol oils”: Cannabinoids content, terpene fingerprint and oxidation stability of European commercially available preparations. Molecules 2018, 23, 1230. [Google Scholar] [CrossRef] [Green Version]
  26. Decreto 9 Novembre 2015: Funzioni di Organismo Statale per la Cannabis Previsto Dagli Articoli 23 e 28 Della Convenzione Unica Sugli Stupefacenti del 1961, Come Modificata nel 1972. Available online: http://www.gazzettaufficiale.it/eli/id/2015/11/30/15A08888/sg;jsessionid=p1rnwNujUKlqQ5azhA%20Q95A__.ntc-as3-guri2a (accessed on 1 May 2020).
  27. Carcieri, C.; Tomasello, C.; Simiele, M.; De Nicolò, A.; Avataneo, V.; Canzoneri, L.; Cusato, J.; Di Perri, G.; D’Avolio, A. Cannabinoids concentration variability in cannabis olive oil galenic preparations. J. Pharm. Pharmacol. 2018, 70, 143–149. [Google Scholar] [CrossRef]
  28. Pacifici, R.; Marchei, E.; Salvatore, F.; Guandalini, L.; Busardò, F.P.; Pichini, S. Evaluation of cannabinoids concentration and stability in standardized preparations of cannabis tea and cannabis oil by ultra-high performance liquid chromatography tandem mass spectrometry. Clin. Chem. Lab. Med. 2017, 55, 1555–1563. [Google Scholar] [CrossRef] [PubMed]
  29. Pacifici, R.; Marchei, E.; Salvatore, F.; Guandalini, L.; Busardò, F.P.; Pichini, S. Evaluation of long-term stability of cannabinoids in standardized preparations of cannabis flowering tops and cannabis oil by ultra-high-performance liquid chromatography tandem mass spectrometry. Clin. Chem. Lab. Med. 2018, 28, 94–96. [Google Scholar] [CrossRef] [PubMed]
  30. Citti, C.; Ciccarella, G.; Braghiroli, D.; Parenti, C.; Vandelli, M.A.; Cannazza, G. Medicinal cannabis: Principal cannabinoids concentration and their stability evaluated by a high performance liquid chromatography coupled to diode array and quadrupole time of flight mass spectrometry method. J. Pharm. Biomed. Anal. 2016, 128, 201–209. [Google Scholar] [CrossRef] [PubMed]
  31. Calvi, L.; Pentimalli, D.; Panseri, S.; Giupponi, L.; Gelmini, F.; Beretta, G.; Vitali, D.; Bruno, M.; Zilio, E.; Pavlovic, R.; et al. Comprehensive quality evaluation of medical Cannabis sativa L. inflorescence and macerated oils based on HS-SPME coupled to GC–MS and LC-HRMS (q-exactive orbitrap®) approach. J. Pharm. Biomed. Anal. 2018, 150, 208–219. [Google Scholar] [CrossRef]
  32. Romano, L.; Hazekamp, A. An overview of galenic preparation methods for medicinal cannabis. Curr. Bioact. Compd. 2019, 15, 174–195. [Google Scholar] [CrossRef]
  33. Romano, L.; Hazekamp, A. Cannabis oil: Chemical evaluation of an upcoming Cannabis-based medicine. Cannabinoids 2013, 1, 1–11. [Google Scholar]
  34. Estratto Oleoso di Infiorescenze Femminili di Cannabis. Available online: https://www.sifap.org/procedure/estrazione-oleosa-di-infiorescenze-femminili-di-cannabi (accessed on 19 September 2021).
  35. Storm, C.; Zumwalt, M.; Macherone, A. Agilent Note Cannabis and Hemp Testing. Dedicated Cannabinoid Potency Testing in Cannabis or Hemp Products Using the Agilent 1220 Infinity II LC System. Available online: https://www.agilent.com/cs/library/applications/application-dedicated-cannabinoid-potency-testing-5991-9285-en-us-agilent.pdf (accessed on 22 May 2020).
  36. Aiello, A.; Pizzolongo, F.; Scognamiglio, G.; Romano, A.; Masi, P.; Romano, R. Effects of supercritical and liquid carbon dioxide extraction on hemp (Cannabis sativa L.) seed oil. Int. J. Food Sci. Technol. 2020, 55, 2472–2480. [Google Scholar] [CrossRef]
  37. Weston-Green, K.; Clunas, H.; Jimenez Naranjo, C. A Review of the Potential Use of Pinene and Linalool as Terpene-Based Medicines for Brain Health: Discovering Novel Therapeutics in the Flavours and Fragrances of Cannabis. Front. Psychiatry 2021, 12, 583211. [Google Scholar] [CrossRef]
  38. Pamplona, F.A.; da Silva, L.R.; Coan, A.C. Potential Clinical Benefits of CBD-Rich Extracts Over Purified CBD in Treatment-Resistant Epilepsy: Observational Data Meta-Analysis. Front. Neurol. 2018, 9, 759. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  39. Bilbrey, J.A.; Ortiz, Y.T.; Felix, J.S.; McMahon, L.R.; Wilkerson, J.L. Evaluation of the Terpenes-Caryophyllene, -Terpineol, and -Terpinene in the Mouse Chronic Constriction Injury Model of Neuropathic Pain: Possible Cannabinoid Receptor Involvement. Psychopharmacology 2021, 239, 1475–1486. [Google Scholar] [CrossRef] [PubMed]
  40. Yoshida, N.; Takada, T.; Yamamura, Y.; Adachi, I.; Suzuki, H.; Kawakami, J. Inhibitory Effects of Terpenoids on Multidrug Resistance-Associated Protein 2- and Breast Cancer Resistance Protein-Mediated Transport. Drug Metab. Dispos. 2008, 36, 1206–1211. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  41. Schmitt, S.; Schaefer, U.F.; Doebler, L.; Reichling, J. Cooperative Interaction of Monoterpenes and Phenylpropanoids on the in Vitro Human Skin Permeation of Complex Composed Essential Oils. Planta Med. 2009, 75, 1381–1385. [Google Scholar] [CrossRef]
  42. Yamane, M.A.; Williams, A.C.; Barry, B.W. Terpene Penetration Enhancers in Propylene Glycol/water Co-Solvent Systems: Effectiveness and Mechanism of Action. J. Pharm. Pharmacol. 1995, 47, 978–989. [Google Scholar] [CrossRef]
  43. Şenyiğit, T.; Padula, C.; Özer, Ö.; Santi, P. Different Approaches for Improving Skin Accumulation of Topical Corticosteroids. Int. J. Pharm. 2009, 380, 155–160. [Google Scholar] [CrossRef]
  44. Furuishi, T.; Kato, Y.; Fukami, T.; Suzuki, T.; Endo, T.; Nagase, H.; Ueda, H.; Tomono, K. Effect of Terpenes on the Skin Permeation of Lomerizine Dihydrochloride. J. Pharm. Pharm. Sci. 2013, 16, 551–563. [Google Scholar] [CrossRef] [Green Version]
  45. Femenía-Font, A.; Balaguer-Fernández, C.; Merino, V.; Rodilla, V.; López-Castellano, A. Effect of Chemical Enhancers on the in Vitro Percutaneous Absorption of Sumatriptan Succinate. Eur. J. Pharm. Biopharm. 2005, 61, 50–55. [Google Scholar] [CrossRef]
  46. Guo, X.; Rong, Y.; Zhang, L.; Ye, J.C. Enhancing Effect of Chiral Enhancer Linalool on Skin Permeation of Naproxen. Acta Acad. Med. Sin. 2016, 38, 55–61. [Google Scholar]
  47. Sexton, M.; Shelton, K.; Haley, P.; West, M. Evaluation of Cannabinoid and Terpenoid Content: Cannabis Flower Compared to Supercritical CO2 Concentrate. Planta Med. 2018, 84, 234–241. [Google Scholar] [CrossRef] [Green Version]
  48. Pang, M.H.; Kim, Y.; Jung, K.W.; Cho, S.; Lee, D.H. A Series of Case Studies: Practical Methodology for Identifying Antinociceptive Multi-Target Drugs. Drug Discov. 2012, 17, 425–434. [Google Scholar] [CrossRef] [PubMed]
Pharmaceutics 15 00870 g001 550
Figure 1. Molecular structures of the main cannabinoids Δ9-tetrahydrocannabinol (THC), Δ9-tetrahydrocannabinolic acid (THCA), cannabinol (CBD) and cannabinolic acid (CBDA), and the monoterpene β-myrcene and sesquiterpene β-caryophyllene.
Figure 1. Molecular structures of the main cannabinoids Δ9-tetrahydrocannabinol (THC), Δ9-tetrahydrocannabinolic acid (THCA), cannabinol (CBD) and cannabinolic acid (CBDA), and the monoterpene β-myrcene and sesquiterpene β-caryophyllene.
Pharmaceutics 15 00870 g001
Pharmaceutics 15 00870 g002 550
Figure 2. Tolotto, manometer, and vacuum valve (a); control system (b); Pharmagear® (c); schematic representation of the automatic process of production of cannabis oils (d); filtration system tools (e); assembled filtration system constituted by the reactor (Tolotto) (1), connector for the vacuum pump (2), and glass cylindric container for the cannabis oil (3) (f).
Figure 2. Tolotto, manometer, and vacuum valve (a); control system (b); Pharmagear® (c); schematic representation of the automatic process of production of cannabis oils (d); filtration system tools (e); assembled filtration system constituted by the reactor (Tolotto) (1), connector for the vacuum pump (2), and glass cylindric container for the cannabis oil (3) (f).
Pharmaceutics 15 00870 g002
Pharmaceutics 15 00870 g003 550
Figure 3. Schematic representation of the SIFAP procedure and TGE and TGE-PE methods for producing cannabis oil using Pharmagear® technology.
Figure 3. Schematic representation of the SIFAP procedure and TGE and TGE-PE methods for producing cannabis oil using Pharmagear® technology.
Pharmaceutics 15 00870 g003
Pharmaceutics 15 00870 g004 550
Figure 4. Representative HPLC chromatogram of Bedrocan oil formulation obtained using TGE method (A), and calibration chromatogram of standards for analytes used in the study (B).
Figure 4. Representative HPLC chromatogram of Bedrocan oil formulation obtained using TGE method (A), and calibration chromatogram of standards for analytes used in the study (B).
Pharmaceutics 15 00870 g004
Table
Table 1. HPLC mobile phase gradient.
Table 1. HPLC mobile phase gradient.
Times (min)0.1% (v/v) Formic Acid Aqueous Phase0.05% (v/v) Formic Acid in Methanol
04060
1.04060
7.02377
8.2595
9.54060
11.04060
Table
Table 2. Concentrations of the active ingredients (mg/mL) after extraction of Bedrocan, FM2, and Pedanios medical plant material using the TGE and TGE-PE methods (n = 3; mean value ± S.D.).
Table 2. Concentrations of the active ingredients (mg/mL) after extraction of Bedrocan, FM2, and Pedanios medical plant material using the TGE and TGE-PE methods (n = 3; mean value ± S.D.).
CompoundPlant Material (g) in Solvent Volume (mL) *Bedrocan
(mg/mL)
(Mean ± S.D.)		FM2
(mg/mL)
(Mean ± S.D.)		Pedanios
(mg/mL)
(Mean ± S.D.)
TGETGE-PETGETGE-PETGE
THC5:5021.084 ± 0.06623.940 ± 2.310 7.811 ± 1.6406.686 ± 0.810 20.784 ± 0.701
10:10021.704 ± 2.17023.215 ± 0.380 7.107 ± 0.5356.894 ± 0.960 19.584 ± 1.420
15:15022.259 ± 1.42023.986 ± 0.900 7.223 ± 0.8807.758 ± 0.590 19.590 ± 0.481
THCA5:501.000 ± 0.4161.126 ± 0.470 0.172 ± 0.170N.Q. 0.548 ± 0.434
10:1001.526 ± 1.1301.555 ± 0.120 0.218 ± 0.380N.Q. 2.521 ± 0.130
15:1501.140 ± 0.3230.254 ± 0.260 N.Q.N.Q. 2.012 ± 1.460
CBD5:50N.Q.N.Q. 8.093 ± 1.48012.126 ± 0.430 N.Q.
10:100N.Q.N.Q. 10.712 ± 0.74011.847 ± 0.830 N.Q.
15:150N.Q.N.Q. 12.424 ± 0.28013.217 ± 0.830 N.Q.
CBDA5:50N.Q.N.Q. 1.386 ± 1.220N.Q. N.Q.
10:100N.Q.N.Q. 0.768 ± 1.3500.685 ± 1.190 N.Q.
15:150N.Q.N.Q. 0.396 ± 0.690N.Q. N.Q.
CBN5:500.150 ± 0.1360.214 ± 0.370 N.Q.0.264 ± 0.460 0.390 ± 0.265
10:1000.169 ± 0.1400.299 ± 0.520 N.Q.0.485 ± 0.420 0.301 ± 0.065
15:1500.260 ± 0.133N.Q. N.Q.N.Q. 0.298 ± 0.084
N.Q.: not quantifiable; * Solvent volumes include the 10 mL olive oil used for washing the reactor.
Table
Table 3. Concentration of the active ingredient cannabinoids (mg/mL) expressed as mean value determined over the period from 2017 to 2019 by analyzing 800 samples for Cannabis flos varieties (Bedrocan and Pedanios) with a content of THC (sum of THC and THCA) close to or higher than 20% w/w, and 350 samples for a Cannabis flos variety (FM2) with a content of THC (sum of THC and THCA) between 5 and 8% w/w and CBD between 7.5 and 12% w/w.
Table 3. Concentration of the active ingredient cannabinoids (mg/mL) expressed as mean value determined over the period from 2017 to 2019 by analyzing 800 samples for Cannabis flos varieties (Bedrocan and Pedanios) with a content of THC (sum of THC and THCA) close to or higher than 20% w/w, and 350 samples for a Cannabis flos variety (FM2) with a content of THC (sum of THC and THCA) between 5 and 8% w/w and CBD between 7.5 and 12% w/w.
Compound Bedrocan/Pedanios
(mg/mL)
(Mean ± S.D.)		FM2
(mg/mL)
(Mean ± S.D.)
THC12.236 ± 3.315.06 ± 1.010
THCA<1.840N.Q.
CBDN.Q.7.268 ± 1.840
N.Q.: not quantifiable.
Table
Table 4. Concentrations of active ingredients (mg/mL) after extraction of Bedrocan medical plant material (5 g) using the TGE and SIFAP methods. The results were determined through analysis of the chromatograms of the oil formulations with final volumes of 50 mL (n = 3; mean value ± standard deviation, S.D.).
Table 4. Concentrations of active ingredients (mg/mL) after extraction of Bedrocan medical plant material (5 g) using the TGE and SIFAP methods. The results were determined through analysis of the chromatograms of the oil formulations with final volumes of 50 mL (n = 3; mean value ± standard deviation, S.D.).
Compound TGE
(mg/mL)
(Mean ± S.D.)		SIFAP
(mg/mL)
(Mean ± S.D.)
THC23.037 ± 1.95616.719 ± 1.330
THCA1.263 ± 0.8711.711 ± 0.504
CBDN.Q.N.Q.
CBDAN.Q.N.Q.
CBN0.376 ± 0.3420.320 ± 0.231
N.Q.: not quantifiable.
Table
Table 5. Terpenes in oil formulations of Bedrocan flos. Concentrations of active ingredients (mg/Kg) after extraction of 5 g of medical plant material using the TGE and TGE-PE methods. The quantities (mean values using duplicate measurements) were determined through GC-MS analysis of an oil formulation with a final volume of 50 mL.
Table 5. Terpenes in oil formulations of Bedrocan flos. Concentrations of active ingredients (mg/Kg) after extraction of 5 g of medical plant material using the TGE and TGE-PE methods. The quantities (mean values using duplicate measurements) were determined through GC-MS analysis of an oil formulation with a final volume of 50 mL.
TerpenesTGE
(mg/Kg)		TGE-PE
(mg/Kg)
α-copaene9.1418.82
nerolidol17.9025.64
cis-geraniol20.9637.83
ylangene25.6345.67
α-bergamotene29.2642.60
τ-gurjunene30.9548.00
borneol38.5448.16
iso-caryophyllene40.0959.06
α-gurjunene41.0848.0
α-selinene47.2372.70
eremophilene49.04104.72
trans-3-caren-2-ol49.5383.68
α-farnesene55.2747.43
β-farnesene66.83728.77
β-selinene69.90139.93
τ-selinene71.8872.70
fenchol85.03108.87
β-phellandrene85.86112.17
2-pinanol105.75193.08
p-mentha-1,3,8-triene106.46199.73
β-trans-ocimene112.94111.49
aromadendrene118.34249.64
α-thujene129.13129.14
δ-guaiene245.52374.41
τ-terpinene271.95299.21
α-pinene307.47371.09
3-carene308.99313.79
selina-3,7-diene350.59532.26
α-humulene354.81677.37
β-pinene373.57439.82
guaia-3,7-diene377.59560.34
cis-carveol393.69557.70
α-terpinene402.40371.84
myrtenol418.47460.76
α-phellandrene443.89482.53
p-cymene501.84493.83
linalol595.96689.23
p-cymen-8-ol738.331421.52
α-terpineol1109.981507.06
caryophillene1224.361762.26
limonene1358.721431.70
β-cis-ocimene3650.653821.75
β-myrcene5144.465457.31
α-terpinolene8544.469038.39
cis-p-menth-2,8-dienolN.Q.71.71
α-limonene diepossideN.Q.82.25
α-guaieneN.Q.109.64
5-caranolN.Q.117.39
Total Concentration28,524.4433,945.96
N.Q.: not quantifiable.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Bongiorno, P.; Lopalco, A.; Casiraghi, A.; Spennacchio, A.; Pitruzzella, A.; Lopedota, A.A.; Minghetti, P.; Denora, N. Digital Technologies Applied to Control the One-Step Process of Cannabis Olive Oil Preparations. Pharmaceutics 2023, 15, 870. https://doi.org/10.3390/pharmaceutics15030870

AMA Style

Bongiorno P, Lopalco A, Casiraghi A, Spennacchio A, Pitruzzella A, Lopedota AA, Minghetti P, Denora N. Digital Technologies Applied to Control the One-Step Process of Cannabis Olive Oil Preparations. Pharmaceutics. 2023; 15(3):870. https://doi.org/10.3390/pharmaceutics15030870

Chicago/Turabian Style

Bongiorno, Paolo, Antonio Lopalco, Antonella Casiraghi, Antonio Spennacchio, Alessandro Pitruzzella, Angela Assunta Lopedota, Paola Minghetti, and Nunzio Denora. 2023. "Digital Technologies Applied to Control the One-Step Process of Cannabis Olive Oil Preparations" Pharmaceutics 15, no. 3: 870. https://doi.org/10.3390/pharmaceutics15030870

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop